Recent share performance and business snapshot

Ascendis Pharma (NasdaqGS:ASND) stock has been under pressure recently, with the share price down about 4% over the past week and about 12% over the past month, closing at US$210.45.

The company, a Denmark based biopharmaceutical group with a market value near US$13.1b, focuses on TransCon based therapies such as SKYTROFA and YORVIPATH, alongside additional endocrinology and oncology candidates in clinical development.

That recent weakness continues a softer trend, with the year to date share price return down 14.24%. Momentum has been fading even as Ascendis Pharma advances its TransCon endocrinology and oncology portfolio.

If Ascendis Pharma’s recent pullback has you reassessing your watchlist, it could be a good time to broaden your search and check out 38 healthcare AI stocks

With Ascendis Pharma trading at US$210.45, a value score of 4, and an estimated intrinsic discount of about 67%, you have to ask: is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 38.5% Undervalued

Ascendis Pharma’s most followed narrative points to a fair value of about $342.08 per share, well above the recent close at $210.45, framing the stock as materially undervalued in that lens.

Partnerships such as the collaboration with Novo Nordisk on once monthly TransCon semaglutide and ex U.S. partners like Teijin for endocrine products extend the TransCon model into larger disease areas and additional geographies. This can add new royalty or collaboration streams alongside product sales and support earnings as R&D productivity improves.

Want to see what sits underneath that valuation gap? The narrative leans on fast compounding revenue, a steep margin shift, and a future earnings multiple more often linked to mature growth leaders.

Result: Fair Value of $342.08 (UNDERVALUED)

However, this hinges on YORVIPATH and TransCon CNP meeting high expectations, while heavy global commercial spending could limit the earnings progress implied in the narrative.

Next Steps

With sentiment split between opportunity and concern, this is a moment to look at the data yourself and decide where you stand, starting with the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Ascendis Pharma is on your radar, do not stop there. Broaden your research now or you risk missing other opportunities that might fit even better.

• Scan for resilient balance sheets and steady fundamentals by running the solid balance sheet and fundamentals stocks screener (46 results) and see which stocks hold up under closer scrutiny.
• Pursue potential mispricings by reviewing the 48 high quality undervalued stocks and compare candidates that stand out on both quality and valuation metrics.
• Hunt for earlier stage opportunities with strong financial characteristics using the 24 elite penny stocks with strong financials before they appear on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.